Horizon breaks with M&A-shy specialty peers to snag Raptor for $800M

Wall Street Bull

Back in June, rumors swirled that Horizon Pharma may be gearing up for some more M&A. And that M&A is here.

Monday, the Dublin drugmaker announced it had inked an $800 million agreement to pick up California’s Raptor Pharmaceuticals, a deal it’ll finance with $675 million of external debt along with cash it has on hand.

The news follows buzz that the Irish pharma was considering selling off a sizable equity stake to an investor to beef up its balance sheet and allow Horizon--whose debt pile measured close to $1.3 billion in June, according to Reuters--in line for new buys.

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

But taking on more debt doesn’t seem to bother the Irish company, which focused Monday on the growth potential of Raptor’s rare-disease products. In particular, it touted more than $300 million in potential peak sales for Procysbi, a treatment for rare metabolic disorder nephropathic cystinosis.

“Horizon Pharma has consistently demonstrated strong commercial execution and ability to generate volume growth for our clinically differentiated medicines,” CEO Timothy Walbert told investors on a conference call, and “we expect the same to occur with Procysbi.”

Horizon has been pretty active in the M&A arena lately--especially considering the slowdown that’s hit some of its specialty peers. Early this year, it sealed a $510 million deal for Crealta, the owner of gout med Krystexxa; and last year, it spent months on a hostile pursuit of California’s Depomed, though that endeavor ultimately failed.

But some of the other players in the specialty arena have run into more trouble in that department. Valeant, for one, has put its trademark buying on hold in the wake of a debt buildup and controversy over its specialty pharmacy connections. Like Horizon, it’s seen its specialty pharmacy program come under the lens at the Department of Justice--and payers have frozen out both companies’ products over their specialty pharmacy links, too. 

- read the release

Related Articles:
Horizon said to explore stake sale as it scouts for M&A
Horizon Pharma joins Valeant in DOJ's specialty pharmacy probe
Horizon shells out $510M for access to gout med Krystexxa
Express Scripts cuts off Horizon-linked pharmacy in widening crackdown
We warned you, Depomed: Horizon pushes down hostile path
Doom for combo meds? Express Scripts, CVS dump Horizon Pharma two-in-one drugs

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.